Qiagen NV

NYSE:QGEN  
47.64
-0.07 (-0.15%)
Positive Earnings Pre-Announcement

Qiagen Increases Outlook For 2020 And 2021

Published: 12/08/2020 07:09 GMT
Qiagen NV (QGEN) - Qiagen Increases Outlook for 2020 and 2021.
Full-year 2020 Net Sales Now Expected to Grow Approximately 22% Cer and Adjusted EPS to Reach $2.13-2.14 Cer.
Full-year 2020 Net Sales Now Expected to Grow Approximately 22% Cer and Adjusted EPS to Reach $2.13-2.14 Cer.
Q4 2020 Sales Outlook Raised to at Least 32% Cer Growth and Adjusted EPS of $0.64-0.65 Cer.
Outlook for Full-year 2021 Raised to 18-20% Cer Net Sales Growth and Adjusted EPS of $2.42-2.46 Cer.
Q4 2020 Sales Outlook Raised to at Least 32% Cer Growth and Adjusted EPS of $0.64-0.65 Cer.
Outlook for Full-year 2021 Raised to 18-20% Cer Net Sales Growth and Adjusted EPS of $2.42-2.46 Cer.
Supervisory Board to Be Expanded to Complement and Enhance Board's Already Extensive Expertise and Experience in Life Sciences and Diagnostics.
Looking Forward to Another Strong Performance in 2021.
Results Are Expected to Be Driven by Qiagen's Focus on Five Pillars of Growth That Leverage Differentiated Testing Solutions Used in Highly Attractive, Growing Markets Involving Life Sciences and Molecular Diagnostics Customers.
Further Company Coverage: .
(berlin Speed Desk).
((frankfurt.
Newsroom@thomsonreuters.
Com;)).
Revenue is expected to be $557.22 Million
Adjusted EPS is expected to be $0.63

Next Quarter Revenue Guidance is expected to be $560.24 Million
Next Quarter EPS Guidance is expected to be $0.59

More details on our Analysts Page.